Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment: A Modeling Study of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Two recent randomized trials produced discordant results when testing the benefits and harms of treatment to reduce blood pressure (BP) in patients with cardiovascular disease (CVD). OBJECTIVE: To perform a theoretical modeling study to identify whether large, clinically important differences in benefit and harm among patients (heterogeneous treatment effects [HTEs]) can be hidden in, and explain discordant results between, treat-to-target BP trials. DESIGN: Microsimulation. DATA SOURCES: Results of 2 trials comparing standard (systolic BP target <140 mm Hg) with intensive (systolic BP target <120 mm Hg) BP treatment and data from the National Health and Nutrition Examination Survey (2013 to 2014). TARGET POPULATION: U.S. adults. TIME HORIZON: 5 years. PERSPECTIVE: Societal. INTERVENTION: BP treatment. OUTCOME MEASURES: CVD events and mortality. RESULTS OF BASE-CASE ANALYSIS: Clinically important HTEs could explain differences in outcomes between 2 trials of intensive BP treatment, particularly diminishing benefit with each additional BP agent (for example, adding a second agent reduces CVD risk [hazard ratio, 0.61], but adding a fourth agent to a third has no benefit) and increasing harm at low diastolic BP. RESULTS OF SENSITIVITY ANALYSIS: Conventional treat-to-target trial designs had poor (<5%) statistical power to detect the HTEs, despite large samples (n > 20 000), and produced biased effect estimates. In contrast, a trial with sequential randomization to more intensive therapy achieved greater than 80% power and unbiased HTE estimates, despite small samples (n = 3500). LIMITATIONS: The HTEs as a function of the number of BP agents only were explored. Simulated aggregate data from the trials were used as model inputs because individual-participant data were not available. CONCLUSION: Clinically important heterogeneity in intensive BP treatment effects remains undetectable in conventional trial designs but can be detected in sequential randomization trial designs. PRIMARY FUNDING SOURCE: National Institutes of Health and U.S. Department of Veterans Affairs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Subgroup analyses in randomized trials: risks of subgroup-specific analyses;
Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.08.009 · Cited by 775
Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001) · Health Technology Assessment · doi:10.3310/hta5330 · Cited by 580
A "SMART" Design for Building Individualized Treatment Sequences
Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D., & Murphy, S. A. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143152 · Cited by 557 · cited 1×
“We hypothesize that to decipher such HTEs, a SMART (sequential, multiple assignment, randomized trial) may be useful (17).”
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A. (2010) · Trials · doi:10.1186/1745-6215-11-85 · Cited by 504
Self-citationThree simple rules to ensure reasonably credible subgroup analyses
Burke, J. F., Sussman, J. B., Kent, D. M., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h5651 · Cited by 312
Self-citation
Cited by
Basu, S., Sussman, J. B., Berkowitz, S. A., Hayward, R. A., & Yudkin, J. S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30221-8 · Cited by 206
“2) HbA1c, mmol/mol 67 (9) 43 (5) 56 (9) Total cholesterol, mg/dL 183.”
Self-citationBasu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002410 · Cited by 77
“A prior simulation study revealed that alternative trial designs that randomize persons in a stepwise fashion to incrementally greater treatment intensity, rather than randomizing between only standard and intensive BP treatment levels, could increase statistical power to detect heterogeneous treatment effects and pro…”
BackgroundSelf-citationBuckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Van Tassell, B. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13248 · Cited by 42
Metadata
- Authors
- Basu, S., Sussman, J. B., & Hayward, R. A.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-03-07
- Volume
- 166
- Issue
- 5
- Pages
- 354-360
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2568119653
- Cited by
- 52
- References
- 8
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.